FDA
-
-
-
-
-
-
-
Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye
-
-
-
-
-
-
-
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May
-
-
-
-
-
-
-
Santhera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
European Medicines Agency Validates Santhera’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy
-
-
-
-
-
-
-
Santhera Announces Improved Liquidity Position
-
-
-
-
-
-
-
Santhera Signs Gene Therapy Agreement with SEAL Therapeutics
-
326,296 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

